TENAX THERAPEUTICS, INC. - Quarter Report: 2010 January (Form 10-Q)

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 10-Q

For the quarterly period ended January 31, 2010

For the transition period from              to             

Commission File Number: 001-34600

OXYGEN BIOTHERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

2530 Meridian Parkway, Suite 3084, Durham, North Carolina 27713

(Address of Principal Executive Office)

919-806-4414

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 (the “Exchange Act”) during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    YES  x    NO  ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data file required to be submitted and posted pursuant to rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or such shorter period that the registrant was required to submit and post such files).    YES  ¨    NO  ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    YES  ¨    NO  x

The number of shares outstanding of each of the issuer’s classes of common stock as of March 15, 2010: 21,310,748 shares of common stock, par value $0.0001.

Table of Contents

INDEX

Table of Contents

Part I-Financial Information

OXYGEN BIOTHERAPEUTICS, INC.

(FORMERLY SYNTHETIC BLOOD INTERNATIONAL, INC.)

(A Development Stage Company)

CONSOLIDATED CONDENSED BALANCE SHEETS

The accompanying notes are an integral part of these Consolidated Condensed Financial Statements.

3

Table of Contents

OXYGEN BIOTHERAPEUTICS, INC.

(FORMERLY SYNTHETIC BLOOD INTERNATIONAL, INC.)

(A Development Stage Company)

CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS

The accompanying notes are an integral part of these Consolidated Condensed Financial Statements.

4

Table of Contents

OXYGEN BIOTHERAPEUTICS, INC.

(FORMERLY SYNTHETIC BLOOD INTERNATIONAL, INC.)

(A Development Stage Company)

CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS

The accompanying notes are an integral part of these Consolidated Condensed Financial Statements.

5

Table of Contents

OXYGEN BIOTHERAPEUTICS, INC.

(FORMERLY SYNTHETIC BLOOD INTERNATIONAL, INC.)

(A Development Stage Company)

CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS - CONTINUED

Non-cash financing activities during the nine months ended January 31, 2010:

Non-cash financing activities during the nine months ended January 31, 2009:

The accompanying notes are an integral part of these Consolidated Condensed Financial Statements.

6

Table of Contents

OXYGEN BIOTHERAPEUTICS, INC.

(A Development Stage Company)

NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS

(UNAUDITED)

1. BASIS OF PRESENTATION

Oxygen Biotherapeutics (the Company) was originally formed as a New Jersey corporation in 1967 under the name Rudmer, David & Associates, Inc., and subsequently changed its name to Synthetic Blood International, Inc. On June 17, 2008, the stockholders of Synthetic Blood International approved the Agreement and Plan of Merger dated April 28, 2008, between Synthetic Blood International and Oxygen Biotherapeutics, Inc., a Delaware corporation.

The accompanying unaudited consolidated condensed financial statements contain all adjustments (consisting only of normal recurring adjustments) which, in the opinion of management, are necessary to present fairly the financial position of the Company as of January 31, 2010, and the results of its operations for the three and nine months ended January 31, 2010 and 2009, and for the period from May 26, 1967 (inception) to January 31, 2010, and its cash flows for the nine months ended January 31, 2010 and 2009, and for the period from May 26, 1967 (inception) to January 31, 2010. Certain information and footnote disclosures normally included in financial statements have been condensed or omitted pursuant to rules and regulations of the U.S. Securities and Exchange Commission (the “Commission”). The Company believes that the disclosures in the financial statements are adequate to make the information presented not misleading. However, the financial statements included herein should be read in conjunction with the financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended April 30, 2009 filed with the Commission on August 12, 2009.

A Certificate of Amendment of the Certificate of Incorporation of Oxygen Biotherapeutics, Inc., as filed with the Secretary of State of the State of Delaware, effectuated the previously announced 1-for-15 reverse stock split of the Company’s common stock. Under the terms of the reverse split, stockholders holding shares of Oxygen Biotherapeutics common stock at the close of business November 6, 2009 received one new Oxygen Biotherapeutics share for every 15 shares held. Fractional shares were rounded up to whole shares. The total number of shares of common stock outstanding was reduced from approximately 296.3 million shares to approximately 19.7 million shares. The number of common shares related to the company’s convertible notes, warrants, and stock options has been proportionately adjusted to reflect the reverse split. Our reverse stock split was accounted for retroactively and reflected in our common stock, warrant, and stock option activity as of and during the periods ended April 30, 2009 and the periods ended January 31, 2010 and 2009.

The accompanying consolidated condensed financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As shown in the accompanying financial statements, the Company is in the development stage and, at January 31, 2010, has an accumulated deficit of $78,699,804. Through January 31, 2010, the Company has sustained operating losses on a monthly basis, and expects to incur operating losses through the remainder of fiscal year 2010. The Company requires substantial funds to complete clinical trials and pursue regulatory approvals.

In view of the matters described above, recoverability of a major portion of the recorded asset amounts shown in the accompanying January 31, 2010 balance sheet is dependent upon continued operations of the Company, which in turn is dependent upon the Company’s ability to generate cash from future operations. This factor raises substantial doubt about the Company’s ability to continue as a going concern. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might be necessary should the Company be unable to continue in existence.

2. RECENT ACCOUNTING PRONOUNCMENTS

The Company adopted new U.S. GAAP guidance related to “Business Combinations” effective for fiscal years beginning after December 15, 2008. The new guidance is based on a fair value model and requires an acquirer to measure all assets acquired and liabilities assumed at their respective fair values at the date of acquisition. This includes measuring noncontrolling (minority) interests at fair value. The guidance establishes principles and requirements for recognizing and measuring goodwill arising from a business combination, and any gain from a bargain purchase. The guidance establishes new disclosure standards and significantly alters the accounting for contingent consideration, pre-acquisition contingencies, in-process research and development and restructuring costs. It requires expensing of acquisition-related costs as incurred. Transactions consummated after the effective date of the guidance apply the guidance prospectively. Existing guidance applies to business combinations consummated prior to December 15, 2008. The Company’s adoption of the new guidance did not have a material impact on its results of operations, financial position, or cash flows.

The Company adopted new U.S. GAAP guidance related to “Noncontrolling Interests in Consolidated Financial Statements” for fiscal years beginning after December 15, 2008. The new guidance, which amends Accounting Research Bulletin No. 51 and provides accounting and reporting standards for noncontrolling (minority) interests in a subsidiary and deconsolidation of a subsidiary, requires noncontrolling interests to be presented separately within equity in the consolidated statement of financial position. Consolidated net income attributable to the parent and noncontrolling interests are to be separately presented on the face of the statement of operations. A change in ownership that does not affect control of a subsidiary is to be accounted for as an equity transaction. A change in ownership that affects control results in recognition of a gain or loss and remeasurement at fair value of any remaining noncontrolling interest. Because the new guidance requires that a noncontrolling interest continue to be attributed its share of losses, a noncontrolling interest could have a negative carrying balance. In the year of adoption, presentation and disclosure requirements will apply retrospectively to all periods presented. The Company’s adoption of the new guidance did not materially affect its consolidated financial statements or results of operations.

7

Table of Contents

The Company adopted new U.S. GAAP guidance related to “The Hierarchy of Generally Accepted Accounting Principles.” The new guidance identifies the sources of accounting principles and the framework for selecting the principles to be used in the preparation of financial statements of nongovernmental entities that are presented in conformity with generally accepted accounting principles in the United States. The guidance will become effective for fiscal periods ended after September 15, 2009. The Company’s adoption of the new guidance did not have a material impact on its results of operations, financial position, or cash flows.

The Company adopted new U.S. GAAP guidance related to “Determining whether an instrument (or Embedded Feature) is indexed to an Entity’s Own Stock” on May 1, 2009. The new guidance provides a framework for determining what types of instruments or embedded features in an instrument held by a reporting entity can be considered indexed to its own stock for the purpose of evaluating the first criteria of the scope exception in paragraph 11(a) of FAS 133. The new guidance is effective for financial statements issued for fiscal years beginning after December 15, 2008 and early application is not permitted. Adopting the guidance did not have a material impact on its results of operations, financial position, or cash flows.

The Company adopted new U.S. GAAP guidance related to “Determining Whether Instruments Granted in Share-Based Payment Transactions Are Participating Securities” on May 1, 2009. The guidance addresses whether instruments granted in share-based payment transactions are participating securities prior to vesting, and therefore, need to be included in the earnings allocation in calculating earnings per share under the two-class method described in FASB Statement of Financial Accounting Standards No. 128, “Earnings Per Share.” The guidance requires companies to treat unvested share-based payment awards that have non-forfeitable rights to dividend or dividend equivalents as a separate class of securities in calculating earnings per share. Adopting the new guidance did not have a material impact on its results of operations, financial position, or cash flows.

The Company adopted new U.S. GAAP guidance related to “Subsequent Events” on May 1, 2009 and as updated as of February 24, 2010. The guidance establishes general standards of accounting for and disclosure of events that occur after the balance sheet date but before financial statements are issued or are available to be issued. The guidance sets forth the circumstances under which an entity should recognize events or transactions occurring after the balance sheet date in its financial statements. The adoption of this new guidance did not have a material impact on our interim unaudited condensed consolidated financial statements.

In August 2009, the FASB amended U.S. GAAP guidance related to “Accounting for Redeemable Equity Instruments.” The guidance addresses the accounting related to distinguishing liabilities from equity, and the classification and measurement of redeemable securities. The adoption of this amended guidance did not have a material impact on our interim unaudited condensed consolidated financial statements.

In October 2008, the FASB proposed new U.S. GAAP guidance related to “Milestones Method of Revenue Recognition.” The guidance addresses the accounting when entities enter into revenue arrangements with multiple payment streams for a single deliverable or a single unit of accounting. The FASB staff could not reach agreement on transition of the new guidance. The Company does not anticipate the adoption of the guidance to have a material impact on its results of operations, financial position, or cash flows.

3. STOCK OPTIONS AND WARRANTS

Stock Options:

The fair value of the Company’s stock options is determined using a Black-Scholes-Merton option pricing model, consistent with the guidance of U.S. GAAP related to “Share-Based Payment” and Securities and Exchange Commission Staff Accounting Bulletin No. 107 (“SAB 107”). The fair value of stock options granted is recognized as compensation expense over the requisite service period. Compensation expense for all share-based payment awards is recognized using the straight-line single-option method. Effective May 1, 2006, the Company adopted the guidance, using a modified prospective application. Prior to May 1, 2006, the Company measured employee and board member compensation cost under the intrinsic method provided by Accounting Principles Board Opinion No. 25, “Accounting for Stock Issued to Employees” (“APB No. 25”) whereby compensation expense is recognized for the excess, if any, of the fair value of the Company’s common stock over the option price on the date the option is granted.

The Company uses the historical stock price volatility to value stock options within the Black-Scholes-Merton option pricing model. The expected term of stock options represents the period of time options are expected to be outstanding and is based on observed historical exercise patterns for the Company, which management believes are indicative of future exercise behavior. For the risk free interest rate, the Company uses the observed interest rates appropriate for the term that the options are expected to be outstanding.

8

Table of Contents

The Company’s net loss for the nine months ended January 31, 2010 and 2009 includes approximately $743,956 and $1,577,679 respectively, of non-cash stock-based compensation costs for the calculated fair value of vested stock options. As of January 31, 2010, there was approximately $258,530 of total unrecognized compensation cost related to non-vested stock option compensation. The fair value of each option grant during the nine months ended January 31, 2010 was calculated at the grant date model using the following assumptions: average risk-free interest rate of 1.73%; average volatility of 101.23%; zero dividend yield for all years; expected life of 3 to10 years; and an estimated forfeiture rate of 8.8%.

During the nine months ended January 31, 2010, the Company received $57,625 and issued 29,001 shares of common stock for the exercise of outstanding options. The exercised options had a weighted average exercise price $1.99 with a cumulative intrinsic value of $115,393.

The following table summarizes the Company’s stock option information during the nine months ended January 31, 2010:

Warrants:

In May 2009, the Company, as part of a consulting agreement with an unrelated third party to provide services in connection with the Company’s Share Purchase Agreement, agreed to extend the term of 151,111 outstanding warrants that were set to expire on May 31, 2009. The term for these warrants was extended through January 31, 2011. The Company recorded $256,181 in compensation expense for the difference in the computed fair values of the modified warrants and the original warrants at the modification date.

In July 2009, the holders of 6,085,280 outstanding warrants accepted an exchange agreement (the “Agreement”). The terms of the Agreement allowed the Company to settle the warrants by paying the holder cash ($0.60/warrant share) and issuing Common Stock ( ¹/2 share/warrant share). In accordance with the Agreement, the Company also had, at its sole discretion, the option to exchange all, a portion of, or none of the holders’ warrants. The original warrants had strike prices ranging from $3.675 - $3.705; a 5-year term; and were issued between April 2006 and October 2008. All of these warrants were valued using the Black-Sholes-Merton Option Pricing Model and were recorded in stockholders’ equity in accordance with U.S. GAAP.

On July 20, 2009, the Company exchanged 4,727,564 warrants in accordance with the terms of the Agreement. The remaining 1,357,716 warrants were reissued to the holders with the original terms. The 4,727,564 warrants were returned to the Company and cancelled in exchange for $2,836,520 in cash and 2,363,767 shares of restricted common stock.

On November 2, 2009, the Company, as part of a consulting agreement with an unrelated third party to provide services in connection with the placement of a Director of the Board, issued 7,408 warrants to Blaise Group International. The warrants were issued with an exercise price of $6.75 and a seven year term. The warrants were valued using the Black-Sholes-Merton Option Pricing Model and the Company recorded $37,339 in compensation expense for the computed fair value of the warrants.

The following table summarizes the Company’s stock warrant information during the nine months ended January 31, 2010:

As of January 31, 2010, potentially issuable shares of common stock included 1,070,038 options, 3,342,024 warrants, and 4,502 conversion shares of outstanding long-term notes payable. Diluted earnings per share for the quarter ended January 31, 2010 was calculated assuming exercise of the above options and warrants using the treasury stock method and conversion of all of the outstanding convertible debt as of the beginning of the quarter using the “if converted method.” Upon conversion of the debt to common stock it is assumed that the Company would recognize $6,675 in additional interest expense for the write off of the related debt discounts, less $353 in discount amortization expense that would be eliminated in the conversion. Each class of potentially issuable shares had an anti-dilutive effect on net loss per share and, as such, the net loss per share amounts are presented without the effect of the potential conversion.

9

Table of Contents

4. INVENTORY

Inventories are recorded at cost using the First-In-First-Out (FIFO) method. Ending inventories are comprised of raw materials and direct costs of manufacturing and valued at the lower of cost or market. Inventories consisted of the following as of January 31, 2010 and April 30, 2009:

5. LICENSING RIGHTS

In May 2008, the Company entered into a license agreement with Virginia Commonwealth University (“Licensor”) whereby Oxygen Biotherapeutics obtained a worldwide, exclusive license to valid claims under three of the Licensor’s patent applications that relate to methods for non-pulmonary delivery of oxygen to tissue and the products based on those valid claims used or useful for therapeutic and diagnostic applications in humans and animals. The license includes the right to sub-license to third parties. The term of the agreement is the life of the patents covered by the patent applications unless by the Company elects to terminate the agreement prior to patent expiration.

The Company has an obligation to diligently pursue product development and pursue, at its expense, prosecution of the patent applications covered by the agreement. The Company paid an initial fee of $50,000 in cash and paid an additional $16,228 to the Licensor as reimbursement of costs paid by the Licensor on patent applications and related work. The Company also issued to the licensor a warrant for the purchase of 33,334 shares of common stock at an exercise price of $6.30 per share that expires May 22, 2013. These warrants were valued at $353,500.

The $16,228 reimbursement costs and the $353,500 value of the 33,334 warrants discussed above were capitalized as licensing rights and are being amortized over the legal life of the underlying patents. In January 2009, the Company exercised its option to include an additional invention in the license agreement. Under the terms of the license agreement, the Company paid to the licensor an additional $25,000 for the exclusive use of intravenous perfluorocarbons emulsions for the treatment of traumatic brain and spinal cord injury. As of January 31, 2010, the Company has capitalized an additional $117,964 in legal costs incurred to maintain the underlying patents. Accumulated amortization on the licensing rights at January 31, 2010 totaled $31,518.

The $50,000 initial fee is fully credited towards future royalty or sublicensing revenue payments to the Licensor. This fee has been accounted for as a deferred cost of sale and is included in other assets at January 31, 2010.

The Company agreed to pay to the Licensor a royalty on net sales of licensed products as follows:

The Company also agrees to pay to the Licensor a percentage of sublicensing revenue received from sub-licensees or other third parties in regards to the licensed patents, equal to 33% of any such third party payments, which may be reduced to 25% if the Company completes pre-clinical studies on a licensed product, reduced further to 20% if the Company completes Phase I clinical studies, reduced further to 17% if the Company completes Phase II clinical studies, and reduced further to 10% if the Company completes Phase III clinical studies on a licensed product.

The Company agreed to pay a $20,000 annual maintenance fee to the Licensor, starting in May 2009 and payable in each following May as long as the agreement is in force. The maintenance fee payments will be fully credited towards future royalty or sublicensing revenue payments to the Licensor. In May 2009, the Company recorded the $20,000 fee as a deferred cost of sale and the payment is reported in other assets at January 31, 2010.

10

Table of Contents

The Company agreed to pay a $50,000 annual minimum royalty to the Licensor, starting in May 2009 and payable in each following May as long as the agreement is in force. The minimum royalty fee payments will be fully credited towards future royalty or sublicensing revenue payments to the Licensor. In May 2009, the Company recorded the $50,000 royalty as a deferred cost of sale and the payment is reported in other assets at January 31, 2010.

Lastly, the agreement provides that the Company will make the following minimum milestone payments to the Licensor, with respect to the first licensed product to achieve each milestone. However, if new licensed products are separately patentable, the same milestone payments shall apply to them.

In November 2009, the Company amended the agreement with the licensor to include a royalty of 4% on the net sales of the perfluorocarbon gel currently marketed under the name Dermacyte.

6. STOCKHOLDERS’ EQUITY

During the nine months ended January 31, 2010:

On June 8, 2009, the Company entered into a securities purchase agreement with JP SPC 1 Vatea, Segregated Portfolio, (“Vatea Fund”), an investment fund formed under the laws of the Cayman Islands (the “Financing Transaction”). Under the terms of the agreement, Vatea Fund purchased on July 10, 2009, 1,333,334 shares of the Company’s restricted common stock at a price of $3.75 per share, or a total of $5 million. Furthermore, the agreement establishes milestones for the achievement of product development and regulatory targets and other objectives, after which Vatea Fund is required to purchase up to 4 million additional shares of common stock at a price of $3.75 per share.

Target dates are the estimated dates by which the corresponding milestone will be accomplished. If a milestone is not achieved by its corresponding target date, then the date is automatically extended for three months. Thereafter, if a milestone is not achieved by its extended target date, the Company and Vatea Fund shall negotiate in good faith agreement on a new target date for the milestone, but if no agreement is reached within 30 days Vatea Fund has no obligation to purchase any shares with respect to that milestone should it subsequently be achieved. The obligation of Vatea Fund to purchase any additional shares upon achieving milestones ends for any milestones not achieved by September 30, 2011. On September 2, 2009, the Company and the Vatea Fund amended the agreement providing an alternative milestone schedule.

11

Table of Contents

In August 2009, the Company received formal approval from Swissmedic to begin Phase II clinical trials of Oxycyte in Switzerland. The Swissmedic approval triggered the first milestone payment in the amended milestone schedule of the Financing Transaction with Vatea Fund. On September 4, 2009, the Company called the milestone on the alternate milestone schedule. In accordance with the Financing Transaction, Vatea Fund was required to purchase an additional 1,600,000 shares of common stock at $3.75 per share, or $6,000,000, on or before December 10, 2009. The initial partial closing occurred on October 29, 2009, pursuant to which 160,000 shares were delivered to Vatea Fund against payment to the Company of $600,000. The second partial closing occurred on November 20, 2009, under which the Company received $2.4 million in cash for 640,000 additional common shares issued to Vatea Fund. The final closing occurred on December 9, 2009, under which the Company received $3 million in cash for 800,000 additional common shares issued to Vatea Fund. In connection with the three closings, the Company paid a consulting fee to Melixia SA for services provided in connection with the securities purchase agreement, which consists of $600,000 in cash and 80,000 shares of our restricted common stock. The Company also paid $90,000 in cash to another consultant who assisted with the securities purchase agreement.

Including the initial investment in July 2009, and assuming all milestones are achieved in a timely manner, the securities purchase agreement provides for a maximum of 5,333,334 shares being sold for $20 million. The number of shares issued is subject to adjustment for stock dividends, stock splits, reverse stock splits, and similar transactions.

Vatea Fund was introduced to the Company through the efforts of two consultants in Europe. For its services, the Company agreed to pay one of the consultants

7. RELATED PARTY TRANSACTIONS

Bruce Spiess, MD was a member of the Board of Directors and a full time employee at Virginia Commonwealth University when the original license agreement and the two amendments to the license agreement were executed.

8. INCOME TAXES

The Company adopted U.S. GAAP guidance related to “Accounting for Uncertainty in Income Taxes, an Interpretation of FASB Statement No. 109.” The guidance prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The evaluation of a tax position in accordance the guidance involves determining whether it is more likely than not that a tax position will be sustained upon examination, based upon the technical merits of the position. A tax position that meets the more-likely-than-not recognition threshold is measured to determine the amount of benefit to recognize in the financial statements. If a tax position does not meet the more-likely-than-not recognition threshold, the financial statements do not recognize a benefit for that position. The adoption of the guidance did not result in a material impact to the Company’s results of operations or its financial condition.

The Company is subject to taxation in the U.S. and a small number of state jurisdictions. The material jurisdictions subject to potential examination by taxing authorities include the U.S., North Carolina and California. From time to time, the Company may be assessed interest or penalties by its tax jurisdictions, although any such assessments historically have been minimal and immaterial to the Company’s financial results. In the event the Company has received an assessment for interest and/or penalties, it has been classified in the financial statements as general and administrative expense.

The utilization of net operating loss carryforwards will likely be limited based on past and future issuances of common and preferred stock due to the ownership change provisions of Internal Revenue Code Section 382.

9. COMMITMENTS AND CONTINGENCIES

Supply Agreement—In November, the Company entered into a three-year exclusive supply agreement with Exflour, an unrelated third party manufacturer of perflourocarbons (“the Supply Agreement”). The Supply Agreement contains a provision by which the Company must pay an additional $100,000 per year to Exfluor in exchange for Exflour’s agreement to supply the FtBu exclusively to the Company, and no other party. The payments are due in quarterly installments of $25,000, payable on the first day of each calendar quarter. The Company paid the first $25,000 quarterly installment in December 2009 and recorded the payment as contract manufacturing expense.

12

Table of Contents

10. SUBSEQUENT EVENTS

On March 2, 2010, the Board approved an annual performance bonus to Christian Stern, CEO for milestones achieved in 2009. Under the terms of his employment contract, Dr. Stern was awarded a $200,000 bonus, payable in cash and shares of common stock for his performance during the calendar year 2009. The cash bonus will be paid in two installments of $50,000 on March 16, 2010 and May 15, 2010. The company issued shares of common stock to Dr. Stern on March 16, 2010 valued at $100,000 based on the closing stock price on March 2, 2010.

13

Table of Contents

Oxygen Biotherapeutics (“the Company,” “we,” “our”) is engaged in the business of developing biotechnology products with a focus on oxygen delivery to tissue. We are currently developing Oxycyte™, a product we believe is a safe and effective oxygen carrier for use in surgical and similar medical situations. We have developed a family of perfluorocarbon based oxygen carriers for use in personal care, topical wound healing, and other topical indications. In addition, we also have under development Vitavent™ and Fluorovent™, a medical device containing saturated perfluocarbon as oxygen exchange fluid for facilitating the treatment of lung conditions.

The nature of our business is to spend years in development and testing of pharmaceutical and medical device products, take products through a lengthy and expensive process of review by domestic and international regulatory authorities, such as U.S. FDA, EMEA, and equivalent. If successful in showing a product is efficacious and obtaining regulatory approval, we intend to commercialize the product in the market for which it is approved [NH1]. During the periods of development and regulatory review we have no product to sell and no revenue. We incur substantial costs pursuing this process, which requires financing from outside sources. We must continue to show progress with our products and be able to locate investors willing to commit their funds to a speculative venture that may ultimately be successful only if we can bring a product to market and gain a meaningful level of market acceptance and penetration. Because of these factors a larger number of biotechnology products under development fail, and there is no assurance that the products we have under development will not suffer the same fate.

We received approval of our Investigational New Drug application for Oxycyte filed with the U.S. Food and Drug Administration (FDA) and began Phase I clinical studies in October 2003, which were completed in December 2003. We submitted a report on the results, which were in line with our expectations, to the FDA along with a Phase II protocol in 2004. Phase II-A clinical studies began in the fourth quarter 2004, and were completed in 2006. A further Phase II study protocol was filed with the FDA in the spring of 2008, but put on clinical hold due to safety concerns raised by the regulatory agency. Management decided to take a radically different approach to trials from the past and filed a revised protocol as a dose-escalation study with the regulatory authorities in Switzerland and Israel. The protocol received Ethic Commission approval in Switzerland and Israel. Swissmedic approved the protocol in August 2009, and the Israel Department of Health in September 2009. The new study began in October 2009 and is currently under way both in Switzerland, and Israel. In the process of continuous improvement of the study, we have concluded that it is feasible to simplify the design and also reduce the number of patients to be enrolled. Study objectives, safety and efficacy endpoints would remain unchanged, and we feel with these optimizations the study could be concluded faster and more economically. We expect to commit a substantial portion of our financial and business resources over the next three years to testing Oxycyte and advancing this product to regulatory approval for use in one or more medical applications.

In July 2009 the Company filed a 510K medical device application for its wound product , Wundecyte™ with the U.S. Food and Drug Administration (FDA). The application has been classified as a combination device by the FDA. Since trials will be needed to substantiate claims the Company has decided to divide the regulatory path for that product into a device application (510K) for the self-oxygenating bandage, and a new drug application (IND) for the oxygen carrying gel. We have completed an initial study design for an animal trial to evaluate Wundecyte’s effectiveness at wound healing, with and without the bandage. This study will look at factors such as time to wound closure and reduction in scar tissue formation as compared to a control group and is anticipated to begin during the next calendar quarter. A prototype for an oxygenating bandage device has been developed and it is currently undergoing testing. The Company intends to follow the testing with a preclinical study covering the treatment of different kinds of wounds. The company is developing clinical research protocols for the treatment of burns, another topical indication based on Oxycyte. The Company intends to develop additional clinical research protocols for topical indications, including the treatment of acne and rosacea. There is no assurance that the topical indications we have under development will prove their claims and be successful commercial products.

In September 2009 the Company started production of its first commercial product under its topical cosmetic line Dermacyte™. The Company produced and sold a limited preproduction batch on November 16, 2009 for orders taken through the company’s website buydermacyte.com. The Company intends to have two Dermacyte products through production and available for retail sale in the first quarter of fiscal 2011. The Company plans to market and sell its products through its website, commercial distributors, and/or license partners during fiscal 2011. Marketing cosmetic products is a very speculative venture and reaching consumers through web-based marketing is dependent on many factors the company has no control of. there is no guarantee the Company will enter into a license or distribution agreement with other parties.

14

Table of Contents

RESULTS OF OPERATIONS

For the three months ended January 31, 2010 and 2009

General and administrative expenses

General and Administrative expenses for the three months ended January 31, 2010 were $1,753,715 compared to $523,463 for the same period in the prior year. During the quarter ended January 31, 2010, the Company incurred approximately $118,000 in costs for direct marketing and market analysis related to the cosmetic topical product line Dermacyte that were not incurred in prior periods. In addition, the company incurred an increase of approximately $303,000 in costs for investor relations over the same period in the prior year for services provided for press releases, road show presentations, investment banking fees, market listing fees and legal costs.

Salaries and wages increased approximately $389,000 due to the increase in headcount from 8 to 21 and goal-based bonus payments over the same period in the prior year. Non-cash, share-based compensation increased $154,604 due to the grant of compensatory options to employees and directors.

The Company expanded its Board of Directors from two outside directors to 7 over the same period in the prior year, resulting in an increase of approximately $60,000 in board related fees for the period. Also, in December 2009, the Company added an additional director to its board. The Company incurred an additional $115,000 in fees paid to a recruiter for the placement.

Research and development expenses

Research and Development expenses for the three months ended January 31, 2010 were $1,011,061, compared to $440,077 for the same period in the prior year. The increase in costs is due primarily to costs incurred for the development of Dermacyte that were not incurred in the prior year and the increase in costs associated with the TBI clinical trials in Switzerland and Israel.

During the three months ended January 31, 2010, the Company incurred approximately $185,000 in costs to develop and commercialize the Dermacyte topical cosmetic. Included in this amount are costs related to gel formulation, testing, and packaging design.

During the three months ended January 31, 2010, the Company incurred approximately $330,000 in costs to associated with the overseas clinical trials. Included in these costs are site set-up fees, CRO costs, and supplying the sites with equipment and Oxycyte.

Salaries and wages increased approximately $75,000 due to the hiring of employees to develop and manage an in-house product and process quality and assurance group.

During the three months ended January 31, 2010, the Company’s costs for regulatory and manufacturing activities increased approximately $130,000 over the same period in the prior year. The increased costs are the result of developing a comprehensive quality manual and contract manufacturing costs for developing cGMP clinical grade Oxycyte.

The Company’s research and develop costs associated with pre-clinical research and supplies decreased approximately $90,000 over the same period in the prior year due to the Company’s focus on furthering the cosmetic, topical, and TBI studies.

Other income and expense

The Company recognized a loss of approximately $18,000 due to foreign currency fluctuations during the three months ended January 31, 2010.

Interest expense decreased approximately $7.4 million, due to the recognition of interest costs associated with our notes payable and related amortization of debt discounts as a result of the conversion of convertible notes during the third quarter of fiscal year 2009.

For the nine months ended January 31, 2010 and 2009

General and administrative expenses

General and Administrative expenses for the nine months ended January 31, 2010 were $5,478,927, compared to $5,462,626 for the same period in the prior year. During the period ended January 31, 2010, the Company incurred approximately $119,000 in costs related to direct marketing and market analysis related to the cosmetic topical product line Dermacyte that were not incurred in prior periods In addition, the company incurred an increase of approximately $420,000 in costs for investor relations over the same period in the prior year for services provided for press releases, road show presentations, investment banking fees, market listing fees and legal costs.

Salaries and wages increased approximately $1,083,885 for the nine months ended January 31, 2010 due to the increase in headcount from 8 to 21 and goal-based bonus payments over the same period in the prior year. Non-cash, share-based compensation decreased $833,722 due to the grant of compensatory options to employees and directors during the prior year. These options were issued to the CEO and new members of the expanded Board of Directors.

15

Table of Contents

The Company expanded its Board of Directors from two outside directors to seven over the same period in the prior year, resulting in an increase of approximately $192,000 in board related fees for the period. Also, during the nine months ended January 31, 2010, the Company incurred an additional $265,000 in fees paid to a recruiter for the placement of two outside directors.

During the nine months ended January 31, 2010, rent expense increased approximately $100,000 (including utilities costs) over the same period in the prior year due to ongoing expansion of the corporate offices in North Carolina.

During the nine months ended January 31, 2010, travel costs increased approximately $150,000 over the same period in the prior year due to increased international travel to Switzerland and Israel, road shows in November and December, and costs related to Board meetings and investor presentations.

For the nine months ended January 31, 2010, the Company reduced consultant costs by approximately $700,000 from the same period in the previous year.

Research and development expenses

Research and Development expenses for the nine months ended January 31, 2010 were $2,169,435, compared to $972,534 for the same period in the prior year. The increase in costs is due primarily to costs incurred for the development of Dermacyte formulations that were not incurred in the prior year and the costs associated with the TBI clinical trials in Switzerland and Israel.

During the nine months ended January 31, 2010, the Company incurred approximately $185,000 in costs to develop and commercialize the Dermacyte topical cosmetic. Included in this amount are costs related to gel formulation, start-up costs for contract manufacturing, and packaging design.

During the nine months ended January 31, 2010, costs to associated with the Oxycyte clinical trials increased approximately $475,000. Included in these costs are site set-up fees, CRO costs, and supplying all of the sites with equipment and Oxycyte.

Salaries and wages increased approximately $231,000 due to the hiring of employees to develop and manage an in-house product and process quality and assurance group.

The Company’s research and develop costs associated with pre-clinical research and supplies decreased approximately $22,000 over the same period in the prior year due to the Company’s focus on furthering the cosmetic, topical, and TBI studies.

Other income and expense

The Company recognized a loss of approximately $18,000 due to foreign currency fluctuations during the three months ended January 31, 2010.

Interest expense decreased approximately $10.1 million, due to the recognition of interest costs associated with our notes payable and related amortization of debt discounts as a result of the conversion of convertible notes during the nine months ended January 31, 2009.

LIQUIDITY AND CAPITAL RESOURCES

Oxygen Biotherapeutics has financed its operations since September 1990 through the issuance of debt and equity securities and loans from stockholders. As of January 31, 2010, we had $3,639,531 of total current assets and working capital of $2,443,220. Our practice is to invest excess cash, where available, in short-term money market investment instruments.

We are in the pre-clinical and clinical trial stages in the development of our products. We are currently conducting Phase II-b clinical trials for the use of Oxycyte in the treatment of severe traumatic brain injury. Even if we are successful with our Phase II-b study, we must then conduct a Phase III clinical study and, if that is successful, file with the FDA and obtain approval of a Biologics License Application to begin commercial distribution, all of which will take more time and funding to complete. Our other products must undergo further development and testing prior to submission to the FDA for approval to initiate clinical trials, which also requires additional funding. Management is actively pursuing private and institutional financing, as well as strategic alliances and/or joint venture agreements to obtain the necessary additional financing and reduce the cost burden related to the development and commercialization of our products. We expect our primary focus will be on funding the continued testing of Oxycyte, since this product is the furthest along in the regulatory review process. Our ability to continue to pursue testing and development of our products beyond 2010 depends on achieving license income, or obtaining outside financial resources. There is no assurance that needed license agreement, or financing will occur or that we will succeed in obtaining the necessary resources.

16

Table of Contents

On June 8, 2009, the Company entered into a securities purchase agreement with JP SPC 1 Vatea, Segregated Portfolio, an investment fund formed under the laws of the Cayman Islands (the “Financing Transaction”). Under the terms of the agreement, Vatea Fund purchased on July 10, 2009, 1.333 million shares of our restricted common stock at a price of $3.75 per share, or a total of $5 million. Furthermore, the agreement establishes milestones for the achievement of product development and regulatory targets and other objectives, after which Vatea Fund is required to purchase 4 million additional shares for $15 million. On September 4, 2009, the Company had accomplished a milestone triggering the next tranche of $6 million in funding and subsequent purchase of 1.6 million of shares. Including the initial investment in July 2009, and assuming all other milestones are achieved in a timely manner, the Financing Transaction provides for the purchase of an additional 1.4 million shares $9 million. The number of shares issued and subject to issue, including share price has been adjusted for the reverse stock split.

In June 2009, the Company commenced a limited offering to persons holding approximately 6 million outstanding warrants to exchange the warrants for cash and restricted common stock. On July 20, 2009, we closed the transaction and cancelled approximately 3.4 million common stock purchase warrants with an exercise price of $3.705 per share and an additional approximately 1.3 million warrants with an exercise price of $3.675 per share, a total of approximately 4.7 million warrants. In exchange for the cancelled warrants the Company issued to the holders 2,363,767 shares of restricted common stock and paid to them $2,836,520 in cash.

Based on our working capital of $2.4 million as of January 31, 2010, we believe we have sufficient capital on hand to continue to fund operations through the first quarter of fiscal 2011.

FORWARD LOOKING STATEMENTS

Except for the historical information contained herein, the discussion and information presented in this report contain forward-looking statements that involve risks and uncertainties. Oxygen Biotherapeutics’ actual results could differ materially from those presented in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in this section and those discussed in the Oxygen Biotherapeutics’ Annual Report on Form 10-K for the year ended April 30, 2009 and subsequent filings made with the Securities and Exchange Commission.

Although Oxygen Biotherapeutics believes that the expectations reflected in the forward-looking statements are reasonable, Oxygen Biotherapeutics cannot guarantee future results, levels of performance or achievements. Moreover, neither Oxygen Biotherapeutics nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements. Oxygen Biotherapeutics is under no obligation to update any of the forward-looking statements after the filing of this report to conform such statements to actual results or changes in expectations.

This Report includes the certifications of our Chief Executive Officer and Chief Financial Officer required by Rule 13a-14 of the Securities Exchange Act of 1934 (the “Exchange Act”). See Exhibits 31.1 and 31.2. This Item 4T includes information concerning the controls and control evaluations referred to in those certifications.

Evaluation of Disclosure Controls and Procedures

Disclosure controls and procedures, as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934 (the “Exchange Act”), are designed to ensure that information required to be disclosed in reports filed or submitted under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in rules and forms adopted by the Securities and Exchange Commission (“SEC”), and that such information is accumulated and communicated to management, including the Chief Executive Officer and the Chief Financial Officer, to allow timely decisions regarding required disclosures.

In connection with the preparation of this report, Oxygen Biotherapeutics’ management, under the supervision and with the participation of the Chief Executive Officer and Chief Financial Officer, assessed the effectiveness of the design and operation of our disclosure controls and procedures as of January 31, 2010. Because of the material weaknesses in our internal control over financial reporting described below, our Chief Executive Officer and Chief Financial Officer conclude that our disclosure controls and procedures were not effective as of January 31, 2010.

Material Weaknesses

In our annual report on Form 10-K for the year ended April 30, 2009, we reported that our disclosure controls and procedures were not effective as of April 30, 2009, because of material weaknesses in our internal control over financial reporting. A “material weakness” is defined under SEC rules as a deficiency, or a combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of a company’s annual or interim financial statements will not be prevented or detected on a timely basis by the Company’s internal controls. As a result of management’s review and evaluations that were completed after the end of fiscal year 2009 related to the preparation of management’s report on internal controls over financial reporting required for this annual report on Form 10-K, management concluded that we had material weaknesses in our control environment and financial reporting process consisting of the following:

17

Table of Contents

Changes in Internal Controls

There were no changes in the Company’s internal control over financial reporting during the nine-month period ended January 31, 2010, that materially affected its internal control over financial reporting.

In August 2009, the Company hired a new Chief Financial Officer to implement corrective measures to remediate the material weaknesses described above. In September 2009, the Company initiated a comprehensive program to assess the areas of significant financial reporting risk. As part of this program, the Company is documenting its internal controls structure to identify and remediate gaps in its internal control framework. These measures, outlined below, are intended both to address the identified material weaknesses and to enhance our overall financial control environment.

We believe the measures described above will remediate the material weaknesses we have identified and strengthen our internal control over financial reporting. We are committed to continuously improve our internal control processes and to diligently and vigorously review our financial reporting controls and procedures. As we evaluate and work to improve our internal control over financial reporting, we may determine to take additional measures to address control deficiencies or determine to modify certain of the remediation measures described above.

18

Table of Contents

Part II-Other Information

Oxygen Biotherapeutics is not presently involved in any legal proceedings and was not involved in any such proceedings during the quarter ended January 31, 2010.

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by Oxygen Biotherapeutics, except where such statements are made in connection with an initial public offering. All statements, other than statements of historical fact, which address activities, actions, goals, prospects, or new developments that we expect or anticipate will or may occur in the future, including such things as expansion and growth of our operations and other such matters are forward-looking statements. Any one or a combination of factors could materially affect our operations and financial condition. These factors include progress in our product development and testing activities, obtaining financing for operations, development of new technologies and other competitive pressures, legal and regulatory initiatives affecting our products, and conditions in the capital markets. Forward-looking statements made by us are based on knowledge of our business and the environment in which we operate as of the date of this report. Because of the factors discussed in the 2009 Annual Report on Form 10-K and in subsequent reports on Form 10-Q, actual results may differ from those in the forward-looking statements.

In the third quarter of fiscal 2010, the Company issued to Christian Stern, its Chief Executive Officer, 1,761 shares of common stock as compensation pursuant to the terms of his compensation agreement. The shares were valued at $10,008.95 at the date of issue.

In the third quarter of fiscal 2010, the Company issued to Richard Kiral, its President and Chief Operating Officer, options to purchase 4,000 shares of common stock pursuant to the terms of his compensation arrangement. The options were granted with a weighted average exercise price of $5.76 and a ten-year term. In January 2010, the Company issued to Dr. Kiral 5,000 shares of restricted common stock for the exercise of outstanding stock options. The Company received $9,000 for the exercise price of the stock option which had an intrinsic value of $20,450 on the exercise date.

In the third quarter of fiscal 2010, the Company issued to Michael Jebsen, its Secretary and Chief Financial Officer, options to purchase 2,001 shares of common stock pursuant to the terms of his compensation arrangement. The options were granted with a weighted average exercise price of $5.97 and a ten-year term

In addition, the Company issued to its employees options to purchase 3,334 shares of common stock with a weighted average exercise price of $5.97 and a ten-year term. The Company also issued options to purchase 40,000 shares of common stock to one of its non-employee directors. These options were issued with an exercise price of $5.18 and a three-year term.

The Company issued 12,001 shares of restricted common stock for the exercise of outstanding stock options. The Company received $21,625 for the exercise price of the stock option which had an intrinsic value of $52,179 on the exercise date.

All of the securities described above were issued in reliance on the exemption from registration set forth in Section 4(2) of the Securities Act of 1933.

None.

On November 12, 2009, Oxygen Biotherapeutics entered into a three-year exclusive supply agreement with Exflour, an unrelated third party manufacturer of perflourocarbons (“the Supply Agreement”) to supply us with sufficient quantities of FtBu to support the production of PFC gels and emulsions. The Supply Agreement contains a provision by which we pay to Exfluor $100,000 per year for the term of the agreement in exchange for Exflour’s agreement to supply the FtBu exclusively to the Company, and no other party. The annual exclusivity payments are payable to Exfuor in installments of $25,000, due at the beginning of each calendar quarter.

19

Table of Contents

On March 2, 2010, the Board approved an annual performance bonus to Christian Stern, CEO for milestones achieved in 2009. Under the terms of his employment contract, Dr. Stern was awarded a $200,000 bonus, payable in cash and shares of common stock for his performance during the calendar year 2009. The cash bonus will be paid in two installments of $50,000 on March 16, 2010 and May 14, 2010. The company issued shares of common stock to Dr. Stern on March 16, 2010 valued at $100,000 based on the closing market price on March 2, 2010.

20

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

March 19, 2010

21